A Phase 2 interventional study of Recombinant COVID-19 Vaccine (CHO cell) and COVID-19 vaccine (Vero cells) in COVID-19 Pneumonia and Coronavirus Infections, sponsored by National Vaccine and Serum Institute, China. Status unknown at 1 site in United Arab Emirates. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-02-02.
Sponsored by National Vaccine and Serum Institute, China (part of Sinopharm) · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies testing CHO cell in COVID-19 — 1 open to participants now, 1 under way, none of them phase 3. CHO cell · COVID-19.
Among the 18 studies testing CHO cell in COVID-19, this one is the 6th largest by enrollment, is one of 9 that started in 2021, is one of 5 in phase 2, and was the 6th registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →1 of the 18 studies testing CHO cell in COVID-19 is open now, in 1 country. Recruiting first, the newest first:
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. · Sites in China
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 7 · Phase 4 1
First in 2020; this study’s year is marked. 9 started in 2021.
This study's enrollment of 1,800 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 714 across the 18 interventional studies. Of the 10 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 18 have an industry lead sponsor. The 5 most frequent:
This study is registered under National Vaccine and Serum Institute, China, one of the names counted as Sinopharm. Under that name alone:
National Vaccine and Serum Institute, China is the lead sponsor of 13 studies on the registry; none are open to participants now.
28 studies in COVID-19 by Sinopharm: none open now, 4 under way, 2 of them phase 3. Of 6 finished, 0 (0%) have results posted.
Among the 28 studies in COVID-19 by Sinopharm, this one is the 8th largest by enrollment, is one of 17 that started in 2021, is one of 4 in phase 2, and was the 6th registered.
Sinopharm’s COVID-19 studies by the year they started, since 2020.
None of the studies under way reaches primary completion within a year.
Among the 18 studies testing CHO cell in COVID-19, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sinopharm’s 28 in COVID-19:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is randomized, blinded and controlled design. Among the randomly selected subjects who have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell), based on a step-wise approach, the subjects will receive one dose of recombinant COVID-19 vaccine sequentially at different shedules of 1-3 months, 3-6 months and ≥ 6 months after two doses of vaccination, and the subjects vaccinated at different schedules will be randomly assigned to different sequential immunization groups. At the same time, each sequential immunization group will be matched with a control group with the inactivated COVID-19 vaccine (vero cells) as the booster dose.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
This study's enrollment of 1,800 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Browse COVID-19 studies →National Vaccine and Serum Institute, China is the lead sponsor of 13 studies on the registry; none are open to participants now.
First submitted after National Vaccine and Serum Institute, China became part of Sinopharm.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 30-90 days
Biological: Recombinant COVID-19 Vaccine (CHO cell) · Biological: COVID-19 vaccine (Vero cells)
Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time is within 91-180 days
Biological: Recombinant COVID-19 Vaccine (CHO cell) · Biological: COVID-19 vaccine (Vero cells)
Subject have been vaccinated with two doses of Inactivated COVID-19 vaccine (Vero cell).The last vaccination time more than 181 days
Biological: Recombinant COVID-19 Vaccine (CHO cell) · Biological: COVID-19 vaccine (Vero cells)
Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell) in the deltoid muscle of the upper arm
Intramuscular injection of Recombinant COVID-19 vaccine (Vero cells) in the deltoid muscle of the upper arm
GMT of anti- SARS-CoV-2 neutralizing antibody
Time frame: 14th day after vaccination
GMT of anti- SARS-CoV-2 neutralizing antibody
Time frame: 28th day after vaccination
4-fold rise of anti- SARS-CoV-2 neutralizing antibody
Time frame: 14th day after vaccination
4-fold rise of anti- SARS-CoV-2 neutralizing antibody
Time frame: 28th day after vaccination
GMT of anti- SARS-CoV-2 neutralizing antibody
Time frame: before vaccination
GMT of anti-SARS-CoV-2 IgG antibody
Time frame: 28th day after vaccination
4-fold rise of anti- SARS-CoV-2 neutralizing antibody
Time frame: before vaccination
4-fold rise of anti- SARS-CoV-2 neutralizing antibody
Time frame: 28th day after vaccination
GMI of anti-SARS-CoV-2 IgG antibody
Time frame: before vaccination
GMI of anti-SARS-CoV-2 IgG antibody
Time frame: 28th day after vaccination
Proportion of neutralizing antibody titer ≥ 1: 16, ≥ 1: 32 and ≥ 1: 64
Time frame: before vaccination
Proportion of neutralizing antibody titer ≥ 1: 16, ≥ 1: 32 and ≥ 1: 64
Time frame: 28th day after vaccination
The incidence and serverity of any adverse reactions
Time frame: within 30 minutes after vaccination
The incidence and serverity of solicited adverse events
Time frame: within 30 minutes after vaccination
The incidence and severity of adverse reactions
Time frame: within 0-7 days after vaccination
The incidence and serverity of solicited adverse events
Time frame: within 0-7 days after vaccination
The incidence and severity of unsolicited adverse reactions
Time frame: within 8-30 days after vaccination
The incidence and serverity of solicited adverse events
Time frame: within 8-30 days after vaccination
The incidence of SAE observed
Time frame: after vaccination and up to 6 months after full course of immunization
The incidence of AESI observed
Time frame: after vaccination and up to 6 months after full course of immunization
The vaccine efficay of recombinant COVID-19 vaccine (CHO cells) against COVID-19, severe cases and deaths
Time frame: 14th day after vaccination
Anti-SARS-CoV-2 neutralizing antibody
Time frame: 3th month, 6th month, 9th month and 12th month after full course of immunization
Anti-SARS-CoV-2 GMT of IgG antibody
Time frame: 3th month, 6th month, 9th month and 12th month after full course of immunization
Proportion of neutralizing antibody titer ≥ 1: 16, ≥ 1: 32 and ≥ 1: 64
Time frame: 3th month, 6th month, 9th month and 12th month after full course of immunization
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2021 (actual). Primary completion is estimated for Nov 2023, 26 months after the start.
Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's planned 26 months is above that.
Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: CHO cell · Vero cell line
National Vaccine and Serum Institute, China →